Engineering Organelle‐Directed DNA Nanodevices: Progress, Pitfalls, and Therapeutic Promise
Advanced Healthcare Materials · 13.11.2026
DOI: 10.1002/adhm.71985 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, online erschienen am 13.11.2026. Verfasst von Muhammad Umar Farooq und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Advanced Studies, Chengdu University, Chengdu, Sichuan, China. Die Arbeit nennt 311 Literaturangaben. Gefördert von: Chengdu University, for the Talent Research Start-up Fund Program.
Abstract (Originalsprache)
Organelle‐level precision can advance cancer nanomedicine beyond nonspecific intracellular delivery toward spatially defined therapeutic action. DNA nanoframeworks, nanodevices, and nanomachines are promising because their sequence, geometry, valency, and dynamic states can be programmed to integrate molecular recognition with sensing, computation, structural reconfiguration, and cargo release. However, organelle targeting is often treated as a localization problem, whereas therapeutic function demands a sequence of biological and engineering steps: systemic stability, tumor‐cell recognition, cellular uptake, endosomal escape, intracellular trafficking, organelle recognition, functional localization, stimulus processing, actuation, and measurable biological response. This review differentiates DNA nanoframeworks, nanodevices, and nanomachines and evaluates their progression from molecular design to intracellular action. We summarize DNA‐containing systems targeting mitochondria, lysosomes, the nucleus, endoplasmic reticulum, and Golgi apparatus, focusing on targeting ligands, trafficking routes, stimulus‐responsive mechanisms, actuation, reporting, and therapeutic function. Non‐DNA systems are considered only as contextual comparators relevant to DNA‐device engineering. Finally, we discuss artificial intelligence and self‐driving laboratories as emerging tools for sequence and structure optimization, image analysis, and closed‐loop experimentation, while separating demonstrated capabilities from the still prospective goal of autonomous intracellular navigation. We also identify design rules, evidence standards, and translational barriers guiding reproducible, mechanistically validated DNA nanodevices for precision intracellular therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Advanced Studies, Chengdu University, Chengdu, Sichuan, China.
- Sichuan Industrial Institute of Antibiotics, College of Pharmacy, Chengdu University, Chengdu, Sichuan, China.
- College of Food and Biological Engineering, Chengdu University, Chengdu, Sichuan, China.
- School of Microelectronics, Shanghai University, Shanghai, China.
- Sino-Swiss Institute of Advanced Technology, Shanghai University, Shanghai, China.
- Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
ORCID-Profile: Muhammad Umar Farooq, Yujiao He, Yongping Wen, Fu Qiang, Lei Zhang, Charles H Lawrie
Förderung
- Chengdu University
- for the Talent Research Start-up Fund Program
Zitieren
APA
Farooq, M. U., He, Y., Wen, Y., Qiang, F., Zhang, L., & Lawrie, C. H. (2026). Engineering Organelle‐Directed DNA Nanodevices: Progress, Pitfalls, and Therapeutic Promise. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71985
Vancouver
Farooq MU, He Y, Wen Y, Qiang F, Zhang L, Lawrie CH. Engineering Organelle‐Directed DNA Nanodevices: Progress, Pitfalls, and Therapeutic Promise. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71985
BibTeX
@article{Farooq2026,
author = {Farooq, Muhammad Umar and He, Yujiao and Wen, Yongping and Qiang, Fu and Zhang, Lei and Lawrie, Charles H},
title = {Engineering Organelle‐Directed DNA Nanodevices: Progress, Pitfalls, and Therapeutic Promise},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71985}
}
EUVIMED